WILLIAM NASSIBWILLIAM JRWILLIAM NASSIB WILLIAM JR9440WILLIAM JR, WILLIAM NASSIBAssociate Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson25301631Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PAScience (New York, N.Y.)Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10; 346(6206):256-9.Science2014-10-10T00:00:002014Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing.1400 Holcombe BlvdHouston77030-4008TXAuthorship 1677892Authorship 1808671Authorship 1821407Authorship 1821451Authorship 1823851Authorship 1827321Authorship 1829731Authorship 1830681Authorship 1842394Authorship 1869894Authorship 1920465Authorship 1929045Authorship 1956644Authorship 19607739809481Ceddia RB, William WN, Curi RGeneral pharmacologyLeptin increases glucose transport and utilization in skeletal muscle in vitro. Gen Pharmacol. 1998 Nov; 31(5):799-801.Gen Pharmacol1998-11-01T00:00:001998Leptin increases glucose transport and utilization in skeletal muscle in vitro.19190590William WN, Kim ES, Herbst RSNature clinical practice. OncologyCetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nat Clin Pract Oncol. 2009 Mar; 6(3):132-3.Nat Clin Pract Oncol2009-01-30T00:00:002009Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck.19247304William WN, Heymach JV, Kim ES, Lippman SMNature reviews. Drug discoveryMolecular targets for cancer chemoprevention. Nat Rev Drug Discov. 2009 Mar; 8(3):213-25.Nat Rev Drug Discov2009-03-01T00:00:002009Molecular targets for cancer chemoprevention.19318668William WN, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ESChestRevisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest. 2009 Sep; 136(3):701-709.Chest2009-03-24T00:00:002009Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data.19687727William WN, Khuri FR, Fossella FV, Glisson BS, Zinner RG, Lee JJ, Herbst RS, Lippman SM, Kim ESAmerican journal of clinical oncologyPhase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy. Am J Clin Oncol. 2010 Apr; 33(2):148-52.Am J Clin Oncol2010-04-01T00:00:002010Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.19704160William WN, Gold KA, Kim ESAnnals of oncology : official journal of the European Society for Medical OncologyGefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options. Ann Oncol. 2009 Sep; 20(9):1455-1457.Ann Oncol2009-09-01T00:00:002009Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.BiostatisticsGI Medical OncologyHead & Neck SurgeryLeukemiaThoracic & Cardiovascular SurgeryThoracic Head & Neck Medical OncologyTranslational Molecular PathologyMD AndersonADEL KEL-NAGGARADEL K EL-NAGGAR8614EL-NAGGAR, ADEL KProfessorJEFFREY NMYERSJEFFREY N MYERS8712MYERS, JEFFREY NProfessorJOHN VICTORHEYMACHJOHN VICTOR HEYMACH9280HEYMACH, JOHN VICTORProfessorJAFFER AAJANIJAFFER A AJANI8473AJANI, JAFFER AProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorBONNIE SGLISSONBONNIE S GLISSON8491GLISSON, BONNIE SProfessorSTEPHEN GSWISHERSTEPHEN G SWISHER8671SWISHER, STEPHEN GProfessorVASSILIKI APAPADIMITRAKOPOULOUVASSILIKI A PAPADIMITRAKOPOULOU8458PAPADIMITRAKOPOULOU, VASSILIKI AProfessorJIUN-KAE JACKLEEJIUN-KAE JACK LEE8607LEE, JIUN-KAE JACKProfessorIGNACIO IVANWISTUBAIGNACIO IVAN WISTUBA9098WISTUBA, IGNACIO IVANProfessor2.157810.00667854254research areas1.305290.021738350coauthor of55.195113.147460similar to1178selected publicationsAuthorship 2162932Authorship 2168851Authorship 2251741Authorship 2255043Authorship 2280891Authorship 2314861Authorship 2318611Authorship 2336731Authorship 2342842Authorship 234561110188625Ceddia RB, William WN, Carpinelli AR, Curi RGeneral pharmacologyModulation of insulin secretion by leptin. Gen Pharmacol. 1999 Feb; 32(2):233-7.Gen Pharmacol1999-02-01T00:00:001999Modulation of insulin secretion by leptin.11145919Ceddia RB, William WN, Curi RFrontiers in bioscience : a journal and virtual libraryThe response of skeletal muscle to leptin. Front Biosci. 2001 Jan 01; 6:D90-7.Front Biosci2001-01-01T00:00:002001The response of skeletal muscle to leptin.19194117William WN, Lee JL, Shin DM, Hong WK, Liu S, Lee JJ, Lippman SM, Khuri FR, Kim ESAmerican journal of clinical oncologyPhase I trial of weekly topotecan and gemcitabine in patients with solid tumors. Am J Clin Oncol. 2009 Feb; 32(1):15-9.Am J Clin Oncol2009-02-01T00:00:002009Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors.19208430Kim ES, Mauer AM, William WN, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RSCancerA phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer. 2009 Apr 15; 115(8):1713-22.Cancer2009-04-15T00:00:002009A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer.20225327William WN, Kies MS, Fossella FV, Liu DD, Gladish G, Tse WH, Lee JJ, Hong WK, Lippman SM, Kim ESCancerPhase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer. 2010 May 15; 116(10):2401-8.Cancer2010-05-15T00:00:002010Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer.21691321William WN, Glisson BSNature reviews. Clinical oncologyNovel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol. 2011 Jun 21; 8(10):611-9.Nat Rev Clin Oncol2011-06-21T00:00:002011Novel strategies for the treatment of small-cell lung carcinoma.22273549William WNCurrent opinion in oncologyOral premalignant lesions: any progress with systemic therapies? Curr Opin Oncol. 2012 May; 24(3):205-10.Curr Opin Oncol2012-05-01T00:00:002012Oral premalignant lesions: any progress with systemic therapies?23639861William WN, Papadimitrakopoulou VACancer prevention research (Philadelphia, Pa.)Optimizing biomarkers and endpoints in oral cancer chemoprevention trials. Cancer Prev Res (Phila). 2013 May; 6(5):375-8.Cancer Prev Res (Phila)2013-05-01T00:00:002013Optimizing biomarkers and endpoints in oral cancer chemoprevention trials.23910471Foy JP, Bertolus C, William WN, Saintigny POtolaryngologic clinics of North AmericaOral premalignancy: the roles of early detection and chemoprevention. Otolaryngol Clin North Am. 2013 Aug; 46(4):579-97.Otolaryngol Clin North Am2013-05-25T00:00:002013Oral premalignancy: the roles of early detection and chemoprevention.24326607D'souza G, Carey TE, William WN, Nguyen ML, Ko EC, Riddell J, Pai SI, Gupta V, Walline HM, Lee JJ, Wolf GT, Shin DM, Grandis JR, Ferris RLJournal of acquired immune deficiency syndromes (1999)Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):603-10.J Acquir Immune Defic Syndr2014-04-15T00:00:002014Epidemiology of head and neck squamous cell cancer among HIV-infected patients.Authorship 2409432Authorship 2410034Authorship 2421541Authorship 2437843Authorship 2504881Authorship 2514502Authorship 2532483Authorship 2558141Authorship 2568954Authorship 26017919846176Ceddia RB, William WN, Lima FB, Curi RThe Journal of endocrinologyLeptin inhibits insulin-stimulated incorporation of glucose into lipids and stimulates glucose decarboxylation in isolated rat adipocytes. J Endocrinol. 1998 Sep; 158(3):R7-9.J Endocrinol1998-09-01T00:00:001998Leptin inhibits insulin-stimulated incorporation of glucose into lipids and stimulates glucose decarboxylation in isolated rat adipocytes.10578212Ceddia RB, Lopes G, Souza HM, Borba-Murad GR, William WN, Bazotte RB, Curi RInternational journal of obesity and related metabolic disorders : journal of the International Association for the Study of ObesityAcute effects of leptin on glucose metabolism of in situ rat perfused livers and isolated hepatocytes. Int J Obes Relat Metab Disord. 1999 Nov; 23(11):1207-12.Int J Obes Relat Metab Disord1999-11-01T00:00:001999Acute effects of leptin on glucose metabolism of in situ rat perfused livers and isolated hepatocytes.10998055Ceddia RB, William WN, Lima FB, Flandin P, Curi R, Giacobino JPEuropean journal of biochemistryLeptin stimulates uncoupling protein-2 mRNA expression and Krebs cycle activity and inhibits lipid synthesis in isolated rat white adipocytes. Eur J Biochem. 2000 Oct; 267(19):5952-8.Eur J Biochem2000-10-01T00:00:002000Leptin stimulates uncoupling protein-2 mRNA expression and Krebs cycle activity and inhibits lipid synthesis in isolated rat white adipocytes.12475384William WN, Ceddia RB, Curi RThe Journal of endocrinologyLeptin controls the fate of fatty acids in isolated rat white adipocytes. J Endocrinol. 2002 Dec; 175(3):735-44.J Endocrinol2002-12-01T00:00:002002Leptin controls the fate of fatty acids in isolated rat white adipocytes.17762342William WN, Zinner RG, Karp DD, Oh YW, Glisson BS, Phan SC, Stewart DJJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerPhase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol. 2007 Aug; 2(8):745-50.J Thorac Oncol2007-08-01T00:00:002007Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.18381950Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CO, Helman JI, Du B, Yueh B, Boyle JOClinical cancer research : an official journal of the American Association for Cancer ResearchPilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res. 2008 Apr 01; 14(7):2095-101.Clin Cancer Res2008-04-01T00:00:002008Pilot randomized phase II study of celecoxib in oral premalignant lesions.19075276Papadimitrakopoulou VA, Lee JJ, William WN, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SMJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol. 2009 Feb 01; 27(4):599-604.J Clin Oncol2008-12-15T00:00:002008Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy.21430184William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, Wistuba II, Lee HYAnnals of oncology : official journal of the European Society for Medical OncologyThe impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. Ann Oncol. 2012 Jan; 23(1):78-85.Ann Oncol2011-03-23T00:00:002011The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival.21558968Buzaid AC, Schmerling RA, Vieira Guedes RA, de Freitas D, William WNMelanoma researchHigh-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy. Melanoma Res. 2011 Aug; 21(4):370-5.Melanoma Res2011-08-01T00:00:002011High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy.23287849William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ, University of Texas M.D. Anderson Lung Cancer Collaborative Research GroupJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerComputed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013 Feb; 8(2):222-8.J Thorac Oncol2013-02-01T00:00:002013Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.Authorship 2641641Authorship 2692171Authorship 2714063Authorship 27148559698815Ceddia RB, William WN, Lima FB, Carpinelli AR, Curi RBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicasPivotal role of leptin in insulin effects. Braz J Med Biol Res. 1998 Jun; 31(6):715-22.Braz J Med Biol Res1998-06-01T00:00:001998Pivotal role of leptin in insulin effects.20225329William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BSCancerWeekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer. 2010 May 15; 116(10):2409-15.Cancer2010-05-15T00:00:002010Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.23108906Beadle BM, William WN, McLemore MS, Sturgis EM, Williams MDHead & neckp16 expression in cutaneous squamous carcinomas with neck metastases: a potential pitfall in identifying unknown primaries of the head and neck. Head Neck. 2013 Nov; 35(11):1527-33.Head Neck2012-10-29T00:00:002012p16 expression in cutaneous squamous carcinomas with neck metastases: a potential pitfall in identifying unknown primaries of the head and neck.23910475Gold KA, Neskey M, William WNOtolaryngologic clinics of North AmericaThe role of systemic treatment before, during, and after definitive treatment. Otolaryngol Clin North Am. 2013 Aug; 46(4):645-56.Otolaryngol Clin North Am2013-05-25T00:00:002013The role of systemic treatment before, during, and after definitive treatment.Authorship 2730881Authorship 276503210094581Ceddia RB, William WN, Curi RInternational journal of obesity and related metabolic disorders : journal of the International Association for the Study of ObesityComparing effects of leptin and insulin on glucose metabolism in skeletal muscle: evidence for an effect of leptin on glucose uptake and decarboxylation. Int J Obes Relat Metab Disord. 1999 Jan; 23(1):75-82.Int J Obes Relat Metab Disord1999-01-01T00:00:001999Comparing effects of leptin and insulin on glucose metabolism in skeletal muscle: evidence for an effect of leptin on glucose uptake and decarboxylation.17252595Maluf FC, William WN, Rigato O, Menon AD, Parise O, Docema MFHead & neckNecrotizing fasciitis as a late complication of multimodal treatment for locally advanced head and neck cancer: a case report. Head Neck. 2007 Jul; 29(7):700-4.Head Neck2007-07-01T00:00:002007Necrotizing fasciitis as a late complication of multimodal treatment for locally advanced head and neck cancer: a case report.Authorship 2899311Authorship 295370124833104William WN, Swisher SGAnnals of surgical oncologyOptimizing surrogate end points for preoperative systemic therapies in non-small cell lung cancers. Ann Surg Oncol. 2014 Sep; 21(9):2813-4.Ann Surg Oncol2014-05-16T00:00:002014Optimizing surrogate end points for preoperative systemic therapies in non-small cell lung cancers.25273079Faiz SA, Balachandran D, Hessel AC, Lei X, Beadle BM, William WN, Bashoura LThe oncologistSleep-related breathing disorders in patients with tumors in the head and neck region. Oncologist. 2014 Nov; 19(11):1200-6.Oncologist2014-10-01T00:00:002014Sleep-related breathing disorders in patients with tumors in the head and neck region.25361796Gay CM, William WN, Wang SA, Oo THJournal of the National Comprehensive Cancer Network : JNCCNThymoma complicated by acquired amegakaryocytic thrombocytopenia and pure red cell aplasia. J Natl Compr Canc Netw. 2014 Nov; 12(11):1505-9.J Natl Compr Canc Netw2014-11-01T00:00:002014Thymoma complicated by acquired amegakaryocytic thrombocytopenia and pure red cell aplasia.25590605Zhang J, Gold KA, Lin HY, Swisher SG, Xing Y, Lee JJ, Kim ES, William WNJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerRelationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol. 2015 Apr; 10(4):682-90.J Thorac Oncol2015-04-01T00:00:002015Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry.25712052William WN, El-Naggar AKCancer prevention research (Philadelphia, Pa.)A novel target for oral cancer chemoprevention? Notch quite, yet?. Cancer Prev Res (Phila). 2015 Apr; 8(4):262-5.Cancer Prev Res (Phila)2015-02-24T00:00:002015A novel target for oral cancer chemoprevention? Notch quite, yet?.25935097Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, Migden M, Thuro BA, Esmaeli BAmerican journal of ophthalmologyHedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Am J Ophthalmol. 2015 Aug; 160(2):220-227.e2.Am J Ophthalmol2015-04-30T00:00:002015Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.26337990El Haddad D, Iliescu C, Yusuf SW, William WN, Khair TH, Song J, Mouhayar ENJournal of the American College of CardiologyOutcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion. J Am Coll Cardiol. 2015 Sep 08; 66(10):1119-28.J Am Coll Cardiol2015-09-08T00:00:002015Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion.74Professor14Associate Professor20530716Byers LA, Holsinger FC, Kies MS, William WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba II, Myers JN, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JVMolecular cancer therapeuticsSerum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Mol Cancer Ther. 2010 Jun; 9(6):1755-63.Mol Cancer Ther2010-06-08T00:00:002010Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.Authorship 3740717Authorship 3740726Authorship 3740734Authorship 3740802Authorship 374081623129742Zhong LP, Zhang CP, Ren GX, Guo W, William WN, Sun J, Zhu HG, Tu WY, Li J, Cai YL, Wang LZ, Fan XD, Wang ZH, Hu YJ, Ji T, Yang WJ, Ye WM, Li J, He Y, Wang YA, Xu LQ, Wang BS, Kies MS, Lee JJ, Myers JN, Zhang ZYJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol. 2013 Feb 20; 31(6):744-51.J Clin Oncol2012-11-05T00:00:002012Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.23515614Zhong LP, Zhu DW, William WN, Liu Y, Ma J, Yang CZ, Yang X, Wang LZ, Li J, Myers JN, Lee JJ, Zhang CP, Zhang ZYMolecular cancer therapeuticsElevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease. Mol Cancer Ther. 2013 Jun; 12(6):1112-21.Mol Cancer Ther2013-03-20T00:00:002013Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease.19139013Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WKCancer prevention research (Philadelphia, Pa.)Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009 Jan; 2(1):14-21.Cancer Prev Res (Phila)2009-01-01T00:00:002009Cyclin D1 and cancer development in laryngeal premalignancy patients.19139014William WN, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VACancer prevention research (Philadelphia, Pa.)High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila). 2009 Jan; 2(1):22-6.Cancer Prev Res (Phila)2009-01-01T00:00:002009High-dose fenretinide in oral leukoplakia.19917840Kies MS, Holsinger FC, Lee JJ, William WN, Glisson BS, Lin HY, Lewin JS, Ginsberg LE, Gillaspy KA, Massarelli E, Byers L, Lippman SM, Hong WK, El-Naggar AK, Garden AS, Papadimitrakopoulou VJournal of clinical oncology : official journal of the American Society of Clinical OncologyInduction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010 Jan 01; 28(1):8-14.J Clin Oncol2009-11-16T00:00:002009Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.23229707El-Sawy T, Sabichi AL, Myers JN, Kies MS, William WN, Glisson BS, Lippman S, Esmaeli BArchives of ophthalmology (Chicago, Ill. : 1960)Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. Arch Ophthalmol. 2012 Dec; 130(12):1608-11.Arch Ophthalmol2012-12-01T00:00:002012Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma.Authorship 841821Authorship 841856Authorship 842256Authorship 842536Authorship 842597Authorship 842691Authorship 843134Authorship 846083Authorship 846613Authorship 847762Authorship 849242Authorship 849801Authorship 850659Authorship 851181Authorship 851637Authorship 853821Authorship 854159Authorship 855845Authorship 855928Authorship 857230Authorship 857489Authorship 858357Authorship 860357Authorship 861049Authorship 863212Authorship 863669Authorship 864945Authorship 865793Authorship 867853Authorship 868046Journal of Pain and Symptom ManagementDexamethasone for Dyspnea in Cancer Patients. Journal of Pain and Symptom Management. 52:8-16.e1.Dexamethasone for Dyspnea in Cancer PatientsBrain Metastasis from Solid Tumors. 3-29.Brain Metastasis from Solid TumorsNature CommunicationsGenomic heterogeneity of multiple synchronous lung cancer. Nature Communications. 7.Genomic heterogeneity of multiple synchronous lung cancerThe Lancet OncologyPathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers. The Lancet Oncology. 15.Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancersCancerRadiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancer. Cancer. Radiation therapy (with or without neck surgery) for phenotypic human papillomavirus-associated oropharyngeal cancerClinical Cancer ResearchA Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clinical Cancer Research. 22:609-620.A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal TransitionCancer Prevention ResearchNew DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. Cancer Prevention Research. 8:1027-1035.New DNA methylation markers and global DNA hypomethylation are associated with oral cancer developmentJournal of the American College of CardiologyErratum. Journal of the American College of Cardiology. 66:2269.ErratumThe Lancet OncologyLocal consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy. The Lancet Oncology. 17:1672-1682.Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapyCancerReply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data Base. Cancer. 122:3411-3412.Reply to radiotherapy for human papillomavirus-positive oropharyngeal cancers in the National Cancer Data BaseCancerRelation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer. Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinomaEGFR Tyrosine Kinase Inhibitors and Monoclonal Antibodies. 406-420.EGFR Tyrosine Kinase Inhibitors and Monoclonal AntibodiesOral OncologyInduction chemotherapy for oral cavity cancer patients. Oral Oncology. 51:1069-1075.Induction chemotherapy for oral cavity cancer patientsJAMA oncologyErlotinib and the risk of oral cancer the erlotinib Prevention of Oral Cancer (EPOC) randomized clinical trial. JAMA oncology. 2:209-216.Erlotinib and the risk of oral cancer the erlotinib Prevention of Oral Cancer (EPOC) randomized clinical trialThyroidReal-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma. Thyroid. 27:81-87.Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid CarcinomaInternational Journal of Radiation Oncology Biology PhysicsReirradiation of Head and Neck Cancers With Proton Therapy. International Journal of Radiation Oncology Biology Physics. 96:30-41.Reirradiation of Head and Neck Cancers With Proton TherapyCancer Prevention ResearchA novel target for oral cancer chemoprevention? Notch quite, yet.. Cancer Prevention Research. 8:262-265.A novel target for oral cancer chemoprevention? Notch quite, yet.Cancer ResearchEvolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancer. Cancer Research. 75:1527-1536.Evolutionary action score of TP53 identifies high-risk mutations associated with decreased survival and increased distant metastases in head and neck cancerNature CommunicationsSTAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody. Nature Communications. 6.STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibodyHead and NeckOutcomes for hypopharyngeal carcinoma treated with organ-preservation therapy. Head and Neck. Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapyFuture OncologyPrognostic factors, predictive markers and cancer biology. Future Oncology. 12:2379-2386.Prognostic factors, predictive markers and cancer biologyNature Reviews Clinical OncologyCetuximab therapy for patients with advanced squamous cell carcinomas of the head and neck. Nature Reviews Clinical Oncology. 6:132-133.Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neckHead and NeckHRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head and Neck. HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cellsOncotargetLong-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma. Oncotarget. 6:18707-18714.Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinomaInternational Journal of Radiation Oncology Biology PhysicsReirradiation of head and neck cancers with intensity modulated radiation therapy. International Journal of Radiation Oncology Biology Physics. 95:1117-1131.Reirradiation of head and neck cancers with intensity modulated radiation therapyJournal of Clinical OncologyProposed staging system for patients with hpv-related oropharyngeal cancer based on nasopharyngeal cancer n categories. Journal of Clinical Oncology. 34:1848-1854.Proposed staging system for patients with hpv-related oropharyngeal cancer based on nasopharyngeal cancer n categoriesHead and NeckRecurrent oral cavity cancer. Head and Neck. Recurrent oral cavity cancerCancer Treatment CommunicationsSquamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinib. Cancer Treatment Communications. 4:34-36.Squamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinibJournal of Clinical OncologyBarriers to a career focus in cancer prevention. Journal of Clinical Oncology. 34:186-193.Barriers to a career focus in cancer preventionCancer Prevention ResearchIn response. Cancer Prevention Research. 2:281-282.In responseD002289Disorders64653060.283337Carcinoma, Non-Small-Cell LungD008175Disorders1353114820.199024Lung NeoplasmsD002294Disorders79254500.312506Carcinoma, Squamous CellD009062Disorders2007120.661925Mouth NeoplasmsD007972Disorders24700.954932Leukoplakia, OralAuthorship 927628128964539William WN, Feng L, Ferrarotto R, Ginsberg L, Kies M, Lippman S, Glisson B, Kim ESJournal of the American Academy of DermatologyGefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol. 2017 Dec; 77(6):1110-1113.e2.J Am Acad Dermatol2017-09-28T00:00:002017Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial.Pathologytrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor